Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanogen Issued Patent

Method described allows hybridization of DNA to be detected while conducting PCR

Nanogen Issued Patent for Method of Monitoring PCR Using Fluorescent Energy Transfer


San Diego, CA | July 07, 2005

Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today it was issued Patent No. 6,911,310, "Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system" by the U.S. Patent and Trademark Office. The '310 patent relates to a method of monitoring polymerase chain reaction (PCR) amplification of nucleic acid (DNA or RNA) using fluorescent resonant energy transfer (FRET), which is an essential part of molecular diagnostics. Marking the 131st patent to issue to Nanogen, it is closely related to the patents previously issued that describe nanofabrication and self-assembly of photonic molecular structures.

The method described in the '310 patent allows hybridization of DNA to be detected while conducting PCR. The process begins with oligonucleotides that are labeled with donor or acceptor fluorophores, each fluorophore illuminating at a unique wavelength of light upon excitation. When a donor fluorophore is excited, it absorbs energy and transfers it to an acceptor fluorophore that is located within a specific distance to the donor. Energy transfer is permitted in this way when two oligonucleotides, one labeled with a donor fluorophore and one with an acceptor fluorophore, are hybridized to a target nucleic acid. Hybridization places the donor and acceptor fluorophores within transfer distance from each other. The transfer of energy brings a shift in the emitted wavelength that can be detected as a change in the color of the light. In the absence of a target, no energy transfer or change in color occurs. By measuring the emission wavelength that results from the energy transfer to the acceptor fluorophore, the presence of the target nucleic acid can be detected.

"Nanogen's research in nanotechnology and fluorescent energy transfer is the continuation of many years of work," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Our growing intellectual property estate includes valuable technologies involving methods of fluorescent energy transfer that can be used for the creation of useful DNA diagnostic assay systems."


About Nanogen:
Nanogen's advanced diagnostics provide researchers, clinicians, physicians and patients worldwide with improved methods and tests that can predict, diagnose and ultimately help treat disease. Nanogen's products include real-time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for molecular diagnostic applications and its line of rapid point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.

For more information, please visit

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

Robert Saltmarsh
Chief Financial Officer of Nanogen, Inc.

Media & Investor Relations Contact:
Pam Lord
Atkins + Associates

Copyright © Nanogen

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016


Hybrid nanostructures hold hydrogen well: Rice University scientists say boron nitride-graphene hybrid may be right for next-gen green cars October 25th, 2016

Nanoantenna lighting-rod effect produces fast optical switches October 24th, 2016

New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

New method increases energy density in lithium batteries: Novel technique may lead to longer battery life in portable electronics and electrical vehicles October 24th, 2016

Patents/IP/Tech Transfer/Licensing

Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

For first time, carbon nanotube transistors outperform silicon September 8th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project